BioTelemetry (BEAT) Tops Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BioTelemetry, Inc. Reports Fourth Quarter 2018 Financial Results
February 21, 2019 4:06 PM ESTMALVERN, Pa., Feb. 21, 2019 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ: BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the fourth quarter ended December 31, 2018.
Quarter Highlights
Recognized quarterly revenue of $103.6 millionReached 12.9% year-over-year revenue growthAchieved 26th consecutive quarter of year-over-year revenue growthReported GAAP net income of $10.4 million, or $0.29 per diluted shareRealized record quarterly adjusted EBITDA of $30.5 million, or 29.4% of revenue... More